Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
Status:
Completed
Trial end date:
2019-08-27
Target enrollment:
Participant gender:
Summary
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with
ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C
lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC)
inclisiran injection(s). The study will be an international multicenter study (non-United
States).